Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
CONCLUSION: All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI) recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively affected in the 3TC/DTG group, lipid profiles were more negatively affected in the EVG/c/TAF/FTC group, although liver and kidney functions were preserved.PMID:37990894 | DOI:10.2174/011570162X266922231107094649 (Source: Current HIV Research)
Source: Current HIV Research - November 22, 2023 Category: Infectious Diseases Authors: Adem Simsek Oguz Karabay Ertugrul Guclu Hande Toptan Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | PMC:PMC10258937 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | PMC:PMC10258937 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | PMC:PMC10258937 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | PMC:PMC10258937 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B
CONCLUSION: Most of the women who started TDF/3TC/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF/3TC/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.PMID:37308909 | PMC:PMC10258937 | DOI:10.1186/s12981-023-00523-1 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - June 12, 2023 Category: Infectious Diseases Authors: Maganizo B Chagomerana Bryna J Harrington Bethany L DiPrete Shaphil Wallie Madalitso Maliwichi Austin Wesevich Jacob N Phulusa Wiza Kumwenda Allan Jumbe Mina C Hosseinipour Source Type: research

Systematic post-mortem analysis of brain tissue from an HIV-1 subtype C viremic decedent revealed a paucity of infection and pathology
This study reports a 38-year-old Zambian female decedent with severe wasting who was on Atripla for antiretroviral therapy. The cause of death was determined to be HIV/AIDS end-stage disease. The QuantStudio 3 Real-Time PCR System analyzed formalin-fixed paraffin-embedded tissue DNA from a systematic sampling of the entire left-brain hemisphere. Plasma and cerebral spinal fluid HIV-1 RNA loads were 576,123 and 14,962 copies/mL, respectively. The lymph node DNA viral load was 2316 copies per 106 cells. Two hundred and six (96.3%) tissue blocks had amplifiable DNA. HIV-1 viral DNA was detected in 35.9% of the blocks, the hig...
Source: Journal of NeuroVirology - October 5, 2022 Category: Neurology Source Type: research

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study
We report the final 72-week postpartum results for efficacy and safety of dolutegravir-based compared with efavirenz-based regimens in mothers and infants.METHODS: DolPHIN-2 was a randomised, open-label trial. Pregnant women in South Africa and Uganda aged at least 18 years, with untreated but confirmed HIV infection and an estimated gestation of at least 28 weeks, initiating antiretroviral therapy in third trimester were eligible for inclusion. Eligible women were randomly assigned (1:1) to receive either dolutegravir-based (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South...
Source: Herpes - July 29, 2022 Category: Infectious Diseases Authors: Thokozile R Malaba Irene Nakatudde Kenneth Kintu Angela Colbers Tao Chen Helen Reynolds Lucy Read Jim Read Lee-Ann Stemmet Megan Mrubata Kelly Byrne Kay Seden Adelline Twimukye Helene Theunissen Eva Maria Hodel Justin Chiong Nai-Chung Hu David Burger Duol Source Type: research